MCID: OVR049
MIFTS: 52

Ovarian Disease

Categories: Endocrine diseases, Genetic diseases, Rare diseases, Reproductive diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Ovarian Disease

Summaries for Ovarian Disease

MedlinePlus: 41 The ovaries are part of the female reproductive system. Women have two ovaries, one on each side of the uterus. Each ovary is about the size and shape of an almond. The ovaries produce and store a woman's eggs. During ovulation, an ovary releases an egg. If that egg is fertilized by a sperm, a pregnancy can occur. Ovaries also make the female hormones estrogen and progesterone. When a woman goes through menopause, her ovaries stop making those hormones and releasing eggs. Problems with the ovaries include: Ovarian cancer Ovarian cysts and polycystic ovary syndrome Primary ovarian insufficiency Ovarian torsion, a twisting of the ovary

MalaCards based summary: Ovarian Disease, also known as ovarian dysfunction, is related to polycystic ovary syndrome and estrogen excess, and has symptoms including pelvic pain and mittelschmerz. An important gene associated with Ovarian Disease is SHBG (Sex Hormone Binding Globulin), and among its related pathways/superpathways are Metabolism of steroid hormones and Transcription_Role of VDR in regulation of genes involved in osteoporosis. The drugs Estradiol and Dydrogesterone have been mentioned in the context of this disorder. Affiliated tissues include ovary, uterus and placenta, and related phenotypes are endocrine/exocrine gland and reproductive system

Disease Ontology 11 Ovarian disease: A female reproductive system disease that is located in the ovary.

Ovarian dysfunction: An ovarian disease that is characterized by irregular or absent ovulation.

Wikipedia: 75 Ovarian diseases refer to diseases or disorders of the... more...

Related Diseases for Ovarian Disease

Diseases in the Ovarian Disease family:

Primary Ovarian Insufficiency 2a Primary Ovarian Insufficiency 2b
Primary Ovarian Insufficiency 3 Primary Ovarian Insufficiency 4
Primary Ovarian Insufficiency 5 Primary Ovarian Insufficiency 6
Primary Ovarian Insufficiency 7 Primary Ovarian Insufficiency 8
Primary Ovarian Insufficiency 9 Primary Ovarian Insufficiency 10
Primary Ovarian Insufficiency 11 Primary Ovarian Insufficiency 12
Primary Ovarian Insufficiency 13 Primary Ovarian Insufficiency 14
Primary Ovarian Insufficiency 15 Primary Ovarian Insufficiency 16
Primary Ovarian Insufficiency 17 Ovarian Insufficiency, Familial

Diseases related to Ovarian Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 398)
# Related Disease Score Top Affiliating Genes
1 polycystic ovary syndrome 32.9 SHBG PRL INS IGFBP1 IGF1 GNRH1
2 estrogen excess 32.5 SHBG PRL GNRH1 FOXL2 CYP19A1 AMH
3 anovulation 32.4 SHBG PRL INS IGFBP1 IGF1 GNRH1
4 ovarian cyst 32.4 SHBG PRL MUC16 GNRH1 CYP19A1 CGA
5 premature menopause 32.4 ZP3 SHBG PRL INS IGF1 GNRH1
6 ovarian hyperstimulation syndrome 32.3 SHBG INS GNRH1 FSHR CYP19A1 CGA
7 hyperandrogenism 31.4 SHBG PRL INS IGFBP1 IGF1 GNRH1
8 hyperinsulinism 31.4 SHBG INS IGFBP1 IGF1 GNRH1
9 amenorrhea 31.4 SHBG PRL INS IGF1 GNRH1 GDF9
10 hyperprolactinemia 31.3 SHBG PRL INS IGF1 GNRH1 CGA
11 type 2 diabetes mellitus 31.2 SHBG PRL MIR27A MIR21 MIR199A1 INS
12 infertility 31.2 ZP3 SHBG PRL IGFBP1 GNRH1 GDF9
13 insulin-like growth factor i 31.1 SHBG PRL INS IGFBP1 IGF1
14 acanthosis nigricans 31.1 SHBG INS IGF1
15 blepharophimosis, ptosis, and epicanthus inversus 30.9 GDF9 FOXL2 CYP19A1 AMH
16 acne 30.9 SHBG PRL INS IGF1 CYP19A1
17 lipoid congenital adrenal hyperplasia 30.9 SHBG PRL INS IGF1 HSD17B1 GNRH1
18 turner syndrome 30.9 SHBG INS IGFBP1 IGF1 FMR1 AMH
19 endometriosis 30.9 MUC16 MIR199A1 MIR141 IGFBP1 HSD17B1 GNRH1
20 ovarian cancer 30.8 MUC16 MIR27A MIR21 MIR199A1 MIR141 INS
21 hypogonadotropic hypogonadism 30.8 SHBG PRL INS IGF1 GNRH1 FSHR
22 hypogonadism 30.6 SHBG PRL INS IGF1 GNRH1 CYP19A1
23 hypothalamic disease 30.6 PRL INS IGF1 GNRH1
24 pituitary gland disease 30.6 PRL INS IGF1 GNRH1 CGA
25 gestational diabetes 30.6 SHBG PRL INS IGFBP1 IGF1
26 empty sella syndrome 30.6 PRL INS IGF1 GNRH1
27 prediabetes syndrome 30.6 SHBG MIR21 INS IGFBP1 IGF1
28 endometrial cancer 30.6 SHBG MUC16 MIR21 MIR199A1 MIR141 INS
29 luteoma 30.6 SHBG FOXL2 CYP19A1 CGA AMH
30 gonadal dysgenesis 30.6 SHBG GDF9 FSHR FOXL2 AMH
31 17-beta hydroxysteroid dehydrogenase iii deficiency 30.6 HSD17B1 GNRH1 AMH
32 galactorrhea 30.6 PRL IGF1
33 oligospermia 30.5 PRL GNRH1 AMH
34 hypothyroidism 30.5 SHBG PRL INS IGF1 GNRH1 FSHR
35 body mass index quantitative trait locus 11 30.5 SHBG PRL MIR27A MIR21 MIR199A1 INS
36 hyperthyroidism 30.5 SHBG PRL INS IGF1 CGA
37 prader-willi syndrome 30.5 PRL INS IGFBP1 IGF1 GNRH1 FMR1
38 myoma 30.5 PRL GNRH1 CYP19A1 AMH
39 vaginal discharge 30.5 IGFBP1 GNRH1 CYP19A1
40 uterine anomalies 30.5 MIR27A MIR21 MIR199A1 MIR141 CYP19A1
41 acromegaly 30.4 SHBG PRL INS IGFBP1 IGF1 GNRH1
42 androgenic alopecia 30.4 SHBG PRL INS IGF1 CYP19A1
43 alopecia 30.4 SHBG PRL IGF1 CYP19A1
44 anorexia nervosa 30.4 SHBG PRL INS IGFBP1 IGF1
45 gynecomastia 30.4 SHBG PRL GNRH1 CYP19A1 CGA
46 premature ovarian failure 1 30.4 PRL GNRH1 GDF9 FSHR FOXL2 FMR1
47 pseudohermaphroditism 30.4 HSD17B1 GNRH1 FSHR FOXL2 CYP19A1 AMH
48 gender incongruence 30.4 SHBG GNRH1 CYP19A1 AMH
49 endometriosis of ovary 30.4 MIR199A1 MIR141 GNRH1 CYP19A1 AMH
50 lipid metabolism disorder 30.4 SHBG MIR21 MIR199A1 INS IGF1

Graphical network of the top 20 diseases related to Ovarian Disease:



Diseases related to Ovarian Disease

Symptoms & Phenotypes for Ovarian Disease

UMLS symptoms related to Ovarian Disease:


pelvic pain; mittelschmerz

MGI Mouse Phenotypes related to Ovarian Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.77 AMH CGA CYP19A1 FMR1 FOXL2 FSHR
2 reproductive system MP:0005389 9.47 AMH CGA CYP19A1 FMR1 FOXL2 FSHR

Drugs & Therapeutics for Ovarian Disease

Drugs for Ovarian Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 104)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
2
Dydrogesterone Approved, Investigational, Withdrawn Phase 4 152-62-5 9051
3
Letrozole Approved, Investigational Phase 4 112809-51-5 3902
4
Polyestradiol phosphate Approved Phase 4 28014-46-2
5
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
6 Hormones Phase 4
7 Hormone Antagonists Phase 4
8 Estrogens Phase 4
9 Estrogen Receptor Antagonists Phase 4
10 Estrogen Antagonists Phase 4
11 Estradiol 3-benzoate Phase 4
12 Estradiol 17 beta-cypionate Phase 4
13 Aromatase Inhibitors Phase 4
14 Progestins Phase 4
15
Carboplatin Approved Phase 3 41575-94-4 10339178 38904
16
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
17
Bevacizumab Approved, Investigational Phase 3 216974-75-3 135329020
18 Albumin-Bound Paclitaxel Phase 3
19 Angiogenesis Inhibitors Phase 3
20 Antineoplastic Agents, Immunological Phase 3
21 Antimitotic Agents Phase 3
22 Tubulin Modulators Phase 3
23
Niraparib Approved, Investigational Phase 2 1038915-60-4 24958200
24
Testosterone Approved, Investigational Phase 2 58-22-0 5408 6013
25
Leuprolide Approved, Investigational Phase 2 53714-56-0 657181
26
Spironolactone Approved Phase 2 1952-01-7, 52-01-7 5833
27
Cisplatin Approved Phase 2 15663-27-1 2767 5702198 441203
28
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3 3680
29
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 3003 5743
30
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
31
Lactitol Approved, Investigational Phase 2 585-86-4 157355
32
Ethinylestradiol Approved Phase 2 57-63-6 5991
33
Desogestrel Approved Phase 2 54024-22-5 40973
34
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
35
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
36
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
37
Olaparib Approved Phase 2 763113-22-0 23725625
38
Lenvatinib Approved, Investigational Phase 2 417716-92-8 9823820
39
Pembrolizumab Approved Phase 2 1374853-91-4 254741536
40
Levoleucovorin Approved, Experimental, Investigational Phase 1, Phase 2 68538-85-2, 58-05-9, 73951-54-9 149436 6006
41
Folic acid Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 59-30-3 6037
42
Exatecan Investigational Phase 1, Phase 2 171335-80-1 18546929 151115
43 Antineoplastic Agents, Hormonal Phase 2
44 Diuretics, Potassium Sparing Phase 2
45 diuretics Phase 2
46 Mineralocorticoids Phase 2
47 Mineralocorticoid Receptor Antagonists Phase 2
48 Anti-Bacterial Agents Phase 2
49 Anti-Infective Agents Phase 2
50 Antibiotics, Antitubercular Phase 2

Interventional clinical trials:

(show all 39)
# Name Status NCT ID Phase Drugs
1 Letrozole Versus Hormonal Preparation in Frozen Cycles of PCOS Patients. Randomized Controlled Study Not yet recruiting NCT05168865 Phase 4 Letrozole 2.5mg
2 A Prospective Randomised Phase III Trial to Evaluate Optimal Treatment Duration of First-line Bevacizumab in Combination With Carboplatin and Paclitaxel in Patients With Primary Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer Completed NCT01462890 Phase 3 Paclitaxel;Carboplatin
3 A Prospective, Controlled, Randomized, Multi-Center, Exploratory Pilot Study Evaluating the Safety and Potential Trends in Efficacy of Adhexil Unknown status NCT00544310 Phase 1, Phase 2
4 A Single-arm, Prospective, Open-label, Phase II Study to Evaluate the Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer Unknown status NCT04556071 Phase 2 Niraparib;Bevacizumab
5 Phase II Study of the Effect of Leuprolide Acetate and Spironolactone on Insulin Resistance in Hyperandrogenic Women With Polycystic Ovarian Disease or Hyperandrogenism Insulin Resistance Acanthosis Nigricans Syndrome Completed NCT00004311 Phase 2 leuprolide acetate;spironolactone
6 Efficacy of the Oncoxin-Viusid® Nutritional Supplement on the Quality of Life of Patients With Advanced or Metastatic Ovarian Epithelial Cancer. Clinical Trial Phase II. Completed NCT03562897 Phase 2
7 Phase 2 Study of Efficacy and Safety of Trabectedin in Subjects With Advanced Ovarian Cancer Completed NCT00050414 Phase 2 Trabectedin;Dexamethasone
8 Prospective Randomized Controlled Trial of Antral Follicle Priming Prior to IVF-ICSI in Previously Diagnosed Low Responders. Completed NCT01310647 Phase 2 Testosterone;Estradiol;CombEq
9 Activity, Tolerability, Safety of Temsirolimus in Women With Ovarian Cancer Who Progressed During Previous Platinum Chemotherapy or Within 6 Months After Therapy or Advanced Endometrial Carcinoma Completed NCT01460979 Phase 2 Temsirolimus
10 Treating Inflammation in Polycystic Ovary Syndrome to Ameliorate Ovarian Dysfunction Recruiting NCT03229408 Phase 2 Salsalate
11 A Prospective, Single-arm, Single-center, Exploratory Phase II Study to Evaluate the Efficacy and Safety of Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Recruiting NCT04566952 Phase 2 Anlotinib;Olaparib
12 A Phase II, Open Lable, Single Arm, Trial to Determine Efficacy and Safety of Lenvatinib in Combination With Pembrolizumab for Platinum- Sensitive Recurrent Ovarian Cancer Recruiting NCT04519151 Phase 2 Pembrolizumab;Lenvatinib
13 Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects Who Have Advanced, Recurrent or Refractory FRα Overexpressing Tumors Recruiting NCT05001282 Phase 1, Phase 2 ELU001
14 A Prospective, Single-arm, Multicenter, Exploratory Phase II Study to Evaluate the Efficacy and Safety of Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer Not yet recruiting NCT04807166 Phase 2 Drug: Anlotinib;Drug: Carboplatin/Paclitaxel
15 89Zr-MMOT0530A PET Imaging in Patients With Unresectable Pancreatic or Platinum-resistant Ovarian Cancer Before Treatment With DMOT4039A. A Separate Study to the Phase I Study Protocol DMO4993g Completed NCT01832116 Phase 1 89Zr-MMOT0530A
16 A Phase 1, Open-label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics of AGS-8M4 Given as Monotherapy in Subjects With Advanced Ovarian Cancer Completed NCT00816764 Phase 1
17 An Open-label Phase 1 Study to Evaluate the Safety and Efficacy of AB-1015 in Patients With Resistant/Refractory Epithelial Ovarian Cancer Recruiting NCT05617755 Phase 1
18 A Phase 1b, Parallel Arm, Multicenter, Open-Label Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Two Different Chemotherapy Regimens in Women With Platinum Resistant or Platinum Sensitive Ovarian Cancer Terminated NCT01016054 Phase 1 Pegylated liposomal doxorubicin (PLD);gemcitabine;carboplatin
19 The Role of Inactive Follicle Stimulating Hormone in Ovarian Dysfunction in Galactosemia Unknown status NCT00619333 follitropin and lutropin
20 Phenotyping and Genotyping of Women Presenting With Ovarian Dysfunction Associated With a Hypergonadotropic Hypo-estrogenic Hormonal Status (WHO III) and Their First and Second Degree Relatives Unknown status NCT01411644
21 Serum Antimullerian Hormone Levels in Patients Who Underwent Hayman Suture for Uterine Atony During Cesarean Section Unknown status NCT03930407
22 A Feasibility Study of Elemental Diet as an Alternative to Parenteral Nutrition for Patients With Inoperable Malignant Bowel Obstruction Unknown status NCT03150992
23 The Role of Pelvic Microbiomes During the Malignant Transformation of Benign Ovarian Diseases Unknown status NCT03388996
24 Timing of Development in Embryos Derived From Women With Polycystic Ovairan Syndrome and Controls Completed NCT01953146
25 Comparison of 2 Techniques of Invasive Mini Surgery: Coelioscopy Mini-trocar and Monotrocar in the Adnexa no Carcinologic Surgery : Forward-looking Observational Study. Completed NCT02885779
26 Evaluation of Ovarian Reserve Using Anti-müllerian Hormone and Antral Follicle Count in Ankylosing Spondylitis: Preliminary Study Completed NCT04209881
27 The nCYT Study: A Powered Study to Evaluate the Sensitivity and Specificity of Cytological Evaluation of Fallopian Tube Samples Collected by the Cytuity in Determining the Presence of Malignancy Completed NCT03593681
28 Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment . Geriatric Oncology Protocol in Aquitaine Country. Completed NCT00210249
29 Feasability of Transgastric Adnexectomy Completed NCT01566955
30 Pathogenesis of Functional Hypothalamic Amenorrhea Completed NCT01674426
31 Prevention of Ovarian Hyperstimulation Syndrome in GnRH Agonist IVF Cycles: Randomized Study Comparing Hydroxyethyl Starch Versus Cabergoline and Hydroxyethyl Starch Completed NCT01530490 Early Phase 1 Cabergoline and Hydroxyethyl Starch;Hydroxyethyl Starch
32 Gonadal Tissue Freezing for Fertility Preservation in Individuals at Risk for Ovarian Dysfunction and Premature Ovarian Insufficiency Recruiting NCT04948658
33 Cumulative Pregnancy Rate With Lower and Higher Dose of Gonadotropin During Controlled Ovarian Hyperstimulation During IVF Among Expected Poor Responders: a Prospective, Randomized Controlled Trial Recruiting NCT05103228 Follitropin Alfa;Follitropin delta;human menopausal gonadotropin
34 Turner Syndrome Minipuberty Study A Prospective, Descriptive Cohortstudy Recruiting NCT04189406
35 Determinants of Age-Related Treatment Effectiveness in Ovarian Cancer: Prospective Study of Pharmacokinetics Patterns and Underlying Biology Active, not recruiting NCT02973750
36 Added Value of Ovarian-Adnexal Reporting and Data System in Evaluation of Ovarian Lesions Not yet recruiting NCT04579575
37 A Novel Ovarian Reserve Monitoring Algorithm for Patients at Risk of Ovarian Injury From Gonadotoxic Therapy Not yet recruiting NCT05048654
38 The Relationship Between Oxidative Stress and Apoptosis of Histopathological Changes Made by Mad Honey Containing Grayanotoxin in the Ovary Not yet recruiting NCT05643599
39 Ovarian Cancer Early Detection Screening Program Terminated NCT01292733 Early Phase 1

Search NIH Clinical Center for Ovarian Disease

Cochrane evidence based reviews: ovarian diseases

Genetic Tests for Ovarian Disease

Anatomical Context for Ovarian Disease

Organs/tissues related to Ovarian Disease:

FMA: Ovary
MalaCards : Ovary, Uterus, Placenta, Pituitary, Breast, T Cells, Thyroid

Publications for Ovarian Disease

Articles related to Ovarian Disease:

(show top 50) (show all 2504)
# Title Authors PMID Year
1
Development of protective agents against ovarian injury caused by chemotherapeutic drugs. 41
36179491 2022
2
Expression of long noncoding RNAs in the ovarian granulosa cells of women with diminished ovarian reserve using high-throughput sequencing. 41
36309699 2022
3
Artificial oocyte activation may improve embryo quality in older patients with diminished ovarian reserve undergoing IVF-ICSI cycles. 41
36085215 2022
4
FSH receptor, KL1/2, P450, and PAPP genes in granulosa-lutein cells from in vitro fertilization patients show a different expression pattern depending on the infertility diagnosis. 53 62
19342032 2010
5
FOXL2 copy number changes in the molecular pathogenesis of BPES: unique cohort of 17 deletions. 53 62
20232352 2010
6
Towards a functional classification of pathogenic FOXL2 mutations using transactivation reporter systems. 53 62
19515849 2009
7
Premature ovarian failure and fragile X female premutation carriers: no evidence for a skewed X-chromosome inactivation pattern. 53 62
19373114 2009
8
Characterization of functionally typical and atypical types of polycystic ovary syndrome. 53 62
19240152 2009
9
FOXL2 mutations and genomic rearrangements in BPES. 53 62
18726931 2009
10
A distribution of two SNPs in exon 10 of the FSHR gene among the women with a diminished ovarian reserve in Ukraine. 53 62
19031050 2009
11
Ovarian dysfunction and FMR1 alleles in a large Italian family with POF and FRAXA disorders: case report. 53 62
17428316 2007
12
A novel polyalanine expansion in FOXL2: the first evidence for a recessive form of the blepharophimosis syndrome (BPES) associated with ovarian dysfunction. 53 62
17089161 2007
13
The empty follicle syndrome. 53 62
17243533 2006
14
Gonadotropin-releasing hormone (GnRH) and its natural analogues: a review. 53 62
16650469 2006
15
FSH receptor gene polymorphisms have a role for different ovarian response to stimulation in patients entering IVF/ICSI-ET programs. 53 62
16758348 2006
16
Influence of intermediate and uninterrupted FMR1 CGG expansions in premature ovarian failure manifestation. 53 62
16361284 2006
17
A new heterozygous mutation of the FOXL2 gene is associated with a large ovarian cyst and ovarian dysfunction in an adolescent girl with blepharophimosis/ptosis/epicanthus inversus syndrome. 53 62
16131596 2005
18
Premature ovarian failure and forkhead transcription factor FOXL2: blepharophimosis-ptosis-epicanthus inversus syndrome and ovarian dysfunction. 53 62
16208278 2005
19
Recurrent severe hyperandrogenism during pregnancy: a case report. 53 62
15790717 2005
20
Molecular cloning of porcine growth differentiation factor 9 (GDF-9) cDNA and its role in early folliculogenesis: direct ovarian injection of GDF-9 gene fragments promotes early folliculogenesis. 53 62
15509699 2004
21
Pregnancy and renal transplantation. 53 62
15013320 2004
22
Electro-acupuncture reverses nerve growth factor abundance in experimental polycystic ovaries in the rat. 53 62
14671415 2004
23
The effect of herbal medicine on nerve growth factor in estradiol valerate-induced polycystic ovaries in rats. 53 62
14992541 2003
24
Molecular approach to common causes of female infertility. 53 62
12475548 2002
25
Human sex hormone-binding globulin variants associated with hyperandrogenism and ovarian dysfunction. 53 62
11927624 2002
26
The female and the fragile X reviewed. 53 62
11480913 2001
27
Long-term GnRH analogue treatment is equivalent to laparoscopic laser diathermy in polycystic ovarian syndrome patients with severe ovarian dysfunction. 53 62
11098021 2000
28
Induction of ovulation after gnRH antagonists. 53 62
10972519 2000
29
Gonadotropins and cytokines affect luteal function through control of apoptosis in human luteinized granulosa cells. 53 62
10770207 2000
30
Free androgen index and leptin are the most prominent endocrine predictors of ovarian response during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. 53 62
10690875 2000
31
Design and evaluation of a ZP3 peptide vaccine in a homologous primate model. 53 62
10321806 1999
32
Treatment of cystic ovarian disease in dairy cows with gonadotrophin-releasing hormone: a field study. 53 62
9990705 1999
33
OVCA (CA125) second generation: technical aspects and serum levels in controls, patients with liver disease, pregnant women and patients with ovarian disease. 53 62
9226027 1997
34
GnRH analog administration in patients with polycystic ovarian disease. 53 62
7589755 1995
35
Regulation of galactose-1-phosphate uridyltransferase gene expression. 53 62
7671960 1995
36
Randomised controlled trial of the use of human chorionic gonadotrophin in recurrent miscarriage associated with polycystic ovaries. 53 62
7947503 1994
37
Elevated serum levels of neopterin and soluble interleukin-2 receptor in patients with ovarian cancer. 53 62
8157196 1994
38
Endocrine features in eutestosteronemic women with polycystic ovaries. 53 62
8150364 1994
39
The combination of gonadotrophin-releasing hormone (GnRH) antagonist and pulsatile GnRH normalizes luteinizing hormone secretion in polycystic ovarian disease but fails to induce follicular maturation. 53 62
8150903 1993
40
Effects of ovarian surgery on the dopaminergic and opioidergic control of gonadotropin and prolactin secretion in women with polycystic ovarian disease. 53 62
8291452 1993
41
Ovarian electrocauterization causes LH-regulated but not insulin-regulated endocrine changes. 53 62
7690311 1993
42
Serum levels of insulin-like growth factor binding protein-1 and ovulatory responses to clomiphene citrate in women with polycystic ovarian disease. 53 62
7685718 1993
43
Lipoprotein(a) and CA125 levels in the plasma of patients with benign and malignant ovarian disease. 53 62
1399109 1992
44
Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. 53 62
1633889 1992
45
Androstenedione as a predictor of ovarian hyperstimulation syndrome. 53 62
1430128 1992
46
Pharmacologic manipulation of fertility. 53 62
1555118 1992
47
Clinical applications of GnRH and its analogues. 53 62
18407075 1992
48
Oral contraceptives increase insulin-like growth factor binding protein-1 concentration in women with polycystic ovarian disease. 53 62
1708731 1991
49
Use of combined exogenous gonadotropins and pulsatile gonadotropin-releasing hormone in patients with polycystic ovarian disease. 53 62
1898892 1991
50
A novel regimen of gonadotropin-releasing hormone (GnRH) antagonist plus pulsatile GnRH: controlled restoration of gonadotropin secretion and ovulation induction. 53 62
2245840 1990

Variations for Ovarian Disease

Expression for Ovarian Disease

Search GEO for disease gene expression data for Ovarian Disease.

Pathways for Ovarian Disease

GO Terms for Ovarian Disease

Cellular components related to Ovarian Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.96 ZP3 SHBG PRL MUC16 INS IGFBP1
2 extracellular space GO:0005615 9.68 AMH CGA GDF9 GNRH1 IGF1 IGFBP1

Biological processes related to Ovarian Disease according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 10.09 MIR27A MIR21 MIR199A1 INS IGF1
2 positive regulation of protein kinase B signaling GO:0051897 9.93 MIR21 MIR199A1 INS IGF1
3 positive regulation of cell population proliferation GO:0008284 9.93 PRL MIR21 MIR141 INS IGF1 GDF9
4 ovarian follicle development GO:0001541 9.91 FSHR FOXL2 AMH
5 positive regulation of vascular associated smooth muscle cell proliferation GO:1904707 9.83 MIR27A MIR21 IGF1
6 activation of protein kinase B activity GO:0032148 9.8 IGF1 INS MIR21
7 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.8 MIR21 INS IGF1 FSHR
8 testosterone biosynthetic process GO:0061370 9.78 HSD17B1 CYP19A1
9 female gonad development GO:0008585 9.77 FSHR FOXL2 CYP19A1
10 positive regulation of cell growth involved in cardiac muscle cell development GO:0061051 9.73 MIR199A1 IGF1
11 follicle-stimulating hormone signaling pathway GO:0042699 9.73 FSHR CGA
12 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.67 MIR21 IGF1
13 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.54 MIR27A MIR21
14 oocyte growth GO:0001555 9.5 GDF9 FOXL2
15 uterus development GO:0060065 9.35 FSHR FOXL2 CYP19A1
16 gonad development GO:0008406 8.92 FSHR CGA AMH

Molecular functions related to Ovarian Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA base-pairing translational repressor activity GO:1903231 9.46 MIR27A MIR21 MIR199A1 MIR141
2 mRNA 3'-UTR binding GO:0003730 9.43 MIR27A MIR21 MIR199A1 MIR141 FMR1
3 hormone activity GO:0005179 9.4 PRL INS IGF1 GNRH1 CGA AMH

Sources for Ovarian Disease

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....